SCHEMBL13723722

SCHEMBL13723722

CC(=O)N1c2ccc(-c3ccc(C(=O)N4CCOCC4)nc3)cc2[C@H](Nc2ccc(C)cn2)C[C@@H]1C

nearest known ligand 0.59

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 20/20 0.59
▸ BRD2 P25440 7/20 0.50
▸ BRD3 Q15059 7/20 0.50
▸ CCL2 P13500 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13724323 0.92 BRD4 (0.63) BRD4BRD2BRD3CCL2
SCHEMBL18871994 0.91 BRD4 (0.58) BRD4BRD2BRD3CCL2
SCHEMBL15437401 0.91 BRD4 (0.60) BRD4BRD2BRD3CCL2
SCHEMBL15437557 0.91 BRD4 (0.58) BRD4BRD2BRD3CCL2
SCHEMBL15450357 0.90 BRD4 (0.66) BRD4BRD2BRD3CCL2
SCHEMBL15437286 0.89 BRD4 (0.54) BRD4BRD2BRD3CCL2
SCHEMBL13724410 0.89 BRD4 (0.54) BRD4BRD2BRD3CCL2
SCHEMBL15437262 0.88 BRD4 (0.49) BRD4BRD2BRD3CCL2
SCHEMBL13723319 0.88 BRD4 (0.49) BRD4BRD2BRD3CCL2
Formic Acid SCHEMBL15437727 0.88 BRD4 (0.62) BRD4BRD2BRD3CCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3168213-B1 TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2018-08-01 — — EP disclosed
EP-3168213-B1 TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2018-08-01 — — EP disclosed
EP-3168213-A1 TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS Glaxosmithkline LLC (US) 2017-05-17 — — EP disclosed
EP-3168213-A1 TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS Glaxosmithkline LLC (US) 2017-05-17 — — EP disclosed
EP-2699551-B1 TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2016-11-16 — — EP disclosed
US-8993554-B2 Tetrahydroquinoline derivatives useful as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2015-03-31 — — US disclosed
US-8993554-B2 Tetrahydroquinoline derivatives useful as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2015-03-31 — — US disclosed
US-8993554-B2 Tetrahydroquinoline derivatives useful as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2015-03-31 — — US disclosed
EP-2699551-A1 TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS Glaxosmithkline LLC (US) 2014-02-26 — — EP disclosed
US-20140031336-A1 Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors GLAXOSMITHKLINE LLC (US) 2014-01-30 — — US disclosed
US-20140031336-A1 Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors GLAXOSMITHKLINE LLC (US) 2014-01-30 — — US disclosed
US-20140031336-A1 Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors GLAXOSMITHKLINE LLC (US) 2014-01-30 — — US disclosed
WO-2012143415-A1 TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031336-A1 Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors BRD4, BRDT, BRD3 BRD4 1/4885BRD2 4/4885BRD3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback